Advertisement

Strahlentherapie und Onkologie

, Volume 191, Issue 3, pp 209–216 | Cite as

Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy

  • Gregor Heiduschka
  • Anja Grah
  • Felicitas Oberndorfer
  • Lorenz Kadletz
  • Gabriela Altorjai
  • Gabriela Kornek
  • Fritz Wrba
  • Dietmar Thurnher
  • Edgar SelzerEmail author
Original article

Abstract

Introduction

In the literature, HPV infection and/or p16 positivity have been consistently demonstrated to correlate with improved response rates in oropharyngeal squamous cell carcinoma (OPSCC) patients treated with primary radiotherapy (RT) alone and in combination with chemotherapy. However, the exact role of HPV/p16 positivity in patients treated with postoperative RT is still unclear.

Methods

We analyzed tumor samples for HPV-DNA and p16 expression and correlated these variables with treatment outcome in a series of 63 consecutively treated oropharyngeal cancer patients (95 % stage III/IV). HPV and p16 analysis were performed using validated test systems. Survival was estimated by the Kaplan–Meier method. Cox proportional hazard regression models were applied to compare the risk of death among patients stratified according to risk factors.

Results

Expression of p16 or high-risk HPV-DNA was detected in 60.3 % and 39.6 % of the tumors, respectively. p16 expression [overall survival (OS) at 2 years: 91 %] as well as HPV infection (OS at 2 years: 95 %) was associated with improved OS. Mean survival in p16-positive patients was 112 months compared to 64.6 months in case of p16 negativity. All HPV-positive tumors stained positive for p16. In a multivariable analysis, p16 positivity was associated with improved OS and with disease-free survival.

Conclusion

p16 expression and HPV infection are strongly associated with the outcome of postoperatively irradiated OPSCC patients. HPV and p16 double-negative OPSCC patients should be regarded as a distinct “very high-risk patient group” that may benefit from intensified or novel treatment combinations.

Keywords

Head and neck cancer Carcinoma, squamous cell Human papillomavirus Surgery Disease-free survival 

Verbessertes Überleben von HPV/p16-positiven Oropharynxkarzinompatienten mit postoperativer Bestrahlung

Zusammenfassung

Hintergrund

In der Literatur wird sowohl die HPV-Infektion als auch eine p16-Positivität in konsistenter Weise mit besseren Ergebnissen für Patienten mit Oropharynxkarzinom (“oropharyngeal squamous cell carcinoma”, OPSCC), die eine primäre Strahlentherapie oder Radiochemotherapie erhalten haben, in Zusammenhang gebracht. Die genaue Rolle von HPV und p16-Positivität bei postoperativ bestrahlten Patienten ist jedoch nach wie vor unklar.

Methoden

Tumormaterial wurde auf HPV-DNA und p16-Expression untersucht, die Ergebnisse wurden mit den Überlebensdaten von 63 konsekutiv behandelten OPSCC-Patienten korreliert (95 % Stadium III/IV). HPV- und p16-Analysen wurden mit Hilfe von validierten Testsystemen durchgeführt. Das Überleben wurde nach der Kaplan-Meier-Methode geschätzt. Cox-Regressionsmodelle wurden für den Vergleich des Sterberisikos der nach Risikofaktoren stratifizierten Patienten verwendet.

Ergebnisse

p16-Expression oder Hochrisiko-HPV-DNA wurde in 60,3 bzw. 39,6 % der Tumoren nachgewiesen. Sowohl p16-Positivität (Gesamtüberleben nach 2 Jahren: 91 %) als auch HPV-Infektion (Gesamtüberleben nach 2 Jahren: 95 %) waren mit verbessertem Gesamtüberleben assoziiert. Das durchschnittliche Überleben bei p16-positiven Tumoren lag bei 112 Monaten, bei Patienten mit p16-negativen Tumoren bei 64,6 Monaten. Alle HPV-positiven Tumoren zeigten eine positive p16-Färbung. In einer multivariablen Analyse war p16 mit verbessertem Gesamtüberleben wie auch krankheitsfreiem Überleben assoziiert.

Schlussfolgerung

p16-Expression und HPV-Infektion sind in postoperativ bestrahlten OPSCC Patienten mit einem verbesserten Überleben assoziiert. HPV- und p16-doppelt-negative OPSCC-Patienten sollten als eine eigenständige „Sehr-hohes-Risiko-Patientengruppe“ betrachtet werden, die von intensivierten oder neuartigen Kombinationstherapien profitieren könnte.

Schlüsselwörter

Kopf-Hals-Tumoren Plattenepithelkarzinom Humaner Papillomvirus Chirurgie Krankheitsfreies Überleben 

Notes

Compliance with ethical guidelines

Conflict of interest

G. Heiduschka, A. Grah, F. Oberndorfer, L. Kadletz, G. Altorjai, G. Kornek, F. Wrba, D. Thurnher, and E. Selzer state that there are no conflicts of interest. All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form).

References

  1. 1.
    Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27:843–850CrossRefPubMedGoogle Scholar
  3. 3.
    Brunner M, Koperek O, Wrba F et al (2012) HPV infection and p16 expression in carcinomas of the minor salivary glands. Eur Arch Otorhinolaryngol 269:2265–2269CrossRefPubMedGoogle Scholar
  4. 4.
    Cooper JS, Pajak TF, Forastiere A et al (1998) Precisely defining high-risk operable head and neck tumors based on RTOG #85–03 and #88–24: targets for postoperative radiochemotherapy? Head Neck 20:588–594CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944CrossRefPubMedGoogle Scholar
  6. 6.
    Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198–1205CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Corvò R (2007) Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85:156–170CrossRefPubMedGoogle Scholar
  8. 8.
    Due AK, Vogelius IR, Aznar MC et al (2012) Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma. Strahlentherapie und Onkologie 188:671–676CrossRefPubMedGoogle Scholar
  9. 9.
    Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269CrossRefPubMedGoogle Scholar
  10. 10.
    Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345:1890–1900CrossRefPubMedGoogle Scholar
  11. 11.
    Gillison ML, D’Souza G, Westra W et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420CrossRefPubMedGoogle Scholar
  12. 12.
    Granata R, Miceli R, Orlandi E et al (2012) Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol 23:1832–1837CrossRefPubMedGoogle Scholar
  13. 13.
    Heiduschka G, Grah A, Oberndorfer F et al (2014) Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab. Strahlenther Onkol 190:832–838CrossRefPubMedGoogle Scholar
  14. 14.
    Jordan RC, Lingen MW, Perez-Ordonez B et al (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945–954CrossRefPubMedGoogle Scholar
  15. 15.
    Licitra L, Perrone F, Bossi P et al (2006) High-Risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636CrossRefPubMedGoogle Scholar
  16. 16.
    Lill C, Kornek G, Bachtiary B et al (2011) Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced. Wien Klin Wochenschr 123:215–221CrossRefPubMedGoogle Scholar
  17. 17.
    Mendenhall WM, Amdur RJ, Hinerman RW, Villaret DB, Siemann DW (2003) Postoperative radiation therapy for squamous cell carcinoma of the head and neck. Am J Otolaryngol 24:41–50CrossRefPubMedGoogle Scholar
  18. 18.
    Mendenhall WM, Hinerman RW, Amdur RJ et al (2006) Postoperative radiotherapy for squamous cell carcinoma of the head and neck. Clin Med Res 4:200–208CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJM, Brakenhoff RH (2013) Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol 49:560–566CrossRefPubMedGoogle Scholar
  20. 20.
    Neuchrist C, Formanek M (2008) Follow up in head and neck cancer. Wien Med Wochenschr 158:273–277CrossRefPubMedGoogle Scholar
  21. 21.
    Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22:1071–1077CrossRefPubMedGoogle Scholar
  22. 22.
    Rades D, Seibold ND, Gebhard MP, Noack F, Thorns C, Schild SE (2013) Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol 189:856–860CrossRefPubMedGoogle Scholar
  23. 23.
    Seibold ND, Schild SE, Gebhard MP, Noack F, Rades D (2013) Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R. Strahlenther Onkol 189:559–565CrossRefPubMedGoogle Scholar
  24. 24.
    Wolff HA, Wolff CRM, Hess CF et al (2013) Secondary primary malignancies in head and neck cancer patients: high prevalence of curable-stage disease. Strahlenther Onkol 189:874–880CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Gregor Heiduschka
    • 1
  • Anja Grah
    • 2
  • Felicitas Oberndorfer
    • 3
  • Lorenz Kadletz
    • 1
  • Gabriela Altorjai
    • 2
  • Gabriela Kornek
    • 4
  • Fritz Wrba
    • 3
  • Dietmar Thurnher
    • 1
  • Edgar Selzer
    • 2
    Email author
  1. 1.Departments of Otorhinolaryngology: Head and Neck SurgeryMedical University of ViennaViennaAustria
  2. 2.Department of RadiotherapyMedical University of ViennaViennaAustria
  3. 3.Department of Clinical PathologyMedical University of ViennaViennaAustria
  4. 4.Medicine I—Division of Clinical OncologyMedical University of ViennaViennaAustria

Personalised recommendations